Introduction
Breast cancer is the second most deadly cancer for women in the United States. About 80% of all newly diagnosed breast cancers are classified as estrogen receptor-a þ (ERa þ ; ref. 1) . ERa, together with progesterone receptor (PgR) and HER2, is part of the standardized clinicopathologic evaluation of breast cancer. Because they provide important information to guide treatment decisions, accurate and reproducible assessment of the levels of these biomarkers is critical. ERa, PgR, and HER2 are routinely assayed using immunohistochemistry (IHC). HER2 amplification is also frequently detected by fluorescence in situ hybridization. However, discordance rates ranging from 9% to 39% were observed for PgR, depending on the techniques used to obtain biopsy specimens (2) . This discrepancy can be partly explained by tumor heterogeneity leading to sampling error during biopsy (3) . Therefore, noninvasive functional imaging of the whole lesion using positron emission tomography (PET) may provide a more complete molecular characterization of the tumor in its native setting. In addition, PET imaging is also an effective approach to monitor advanced metastatic disease during antitumor therapy when repeated biopsies may not be possible.
[ 18 (4, 5) . [ 18 F]FES is an estradiol analog that binds to ERa with high affinity and selectivity (6) . Differences in FES uptake in multiple tumor sites within the same patient have demonstrated heterogeneity of metastases and highlight the value of using functional PET imaging to monitor changes in tumor characteristics with disease progression (7) . In addition, tumor FES uptake before endocrine treatment is correlated with subsequent clinical response to therapy (8) (9) (10) . Finally, blockade of tumor FES uptake after the initiation of tamoxifen or fulvestrant treatment is indicative of the pharmacodynamic effectiveness of the dosing schedule (11) . Together, these approaches underscore the utilities of functional FES-PET.
Although pretreatment ERa expression, as measured by IHC or FES-PET, is predictive for response to endocrine therapies, about 40% to 60% of ERa þ or FES-PET þ patients do not derive longterm benefits from endocrine treatment (8, 12) . Because PgR expression is directly upregulated by activation of ERa signaling, we hypothesize that monitoring PgR expression before and during therapy might provide insights into the functional status of ERa activation and thus the susceptibility of the tumor cells to respond to antiestrogens or estrogen deprivation therapies. [ 18 F]FFNP binds PgR with high affinity, and targets PgR-rich, but not PgR-poor, organs with high selectivity (13) . In clinical studies, the ratio of FFNP uptake in the primary breast cancer lesion over the contralateral normal breast is closely correlated with results from PgR IHC (5). Therefore, FFNP-PET is an approach well suited for following the rapid changes of PgR levels in vivo without the need for repeated biopsies.
Using a preclinical model of ERa þ breast cancer, we previously demonstrated that antitumor treatment with the ERa antagonist fulvestrant reduced tumor FFNP uptake in fulvestrant-sensitive tumors compared with untreated tumors (14) . Interestingly, no difference in tumor FFNP uptake was observed between fulvestrant-resistant mammary tumors and untreated tumors, suggesting that the difference in FFNP tumor uptake may differentiate between endocrine responsive and nonresponsive breast cancers (14) . As opposed to our previous study that focused on posttreatment FFNP-PET, our goal in this study was to test the hypothesis that serial FFNP-PET imaging, before and after initiation of estrogen deprivation treatment, is feasible and effective in monitoring the acute functional changes of ERa signaling and predicting the ultimate response of the tumor. In addition, this study was also designed to directly compare the efficacy of FFNP-PET with FES-PET and FDG-PET as imaging biomarkers predictive of the success of endocrine treatment. Because neoadjuvant endocrine treatment of breast cancer is increasingly being implemented to assess tumor responsiveness before surgery and to guide treatment strategies after surgery, our findings that FFNP-PET is more effective than FES-PET and FDG-PET in predicting endocrine responsiveness provide strong support for noninvasive functional imaging as an informative imaging modality.
Materials and Methods

Cell cultures
The maintenance of the ERa þ PgR þ STAT1 À/À mammary tumor cell lines SSM2 and SSM3 has been described (15 (20, 21) . Dexamethasone
Translational Relevance
Although endocrine therapies are the standard-of-care for patients with estrogen receptor-alpha-positive (ERa þ ) breast cancer, about half of the patients do not benefit from these treatments due to intrinsic or acquired resistance. Therefore, biomarkers that predict tumor responsiveness to endocrine therapies are highly valuable for identifying patients who will require alternative treatments. Noninvasive functional PET imaging offers a unique opportunity to serially follow the molecular changes in tumors in response to therapies. Using preclinical models of (0.5 mmol) or R5020 (0.055 mmol) was injected into SSM3-bearing mice immediately before the injection of [
18 F]FFNP. For the in vivo tissue biodistribution assays, organs were harvested at 1 hour after injection and the radioactivity was measured. The percentage of injected dose per gram (% ID/ g) of tissue was analyzed. For small-animal mPET/CT studies, tumor-bearing mice were imaged before surgery (either shamoperation or ovariectomy; day 0), and 3 and 4 days after surgery (days 3 and 4). Because glucose levels are known to affect [ 18 F]FDG uptake, tumor-bearing mice were fasted overnight the day before FDG imaging. For the MCF7 tumor study, estradiol was withdrawn from drinking water for 6 days starting on day 0. PET and CT images were acquired and analyzed as described previously (14) . Briefly, mice anesthetized with 1.5% to 2.0% isoflurane were scanned in the supine position in a small-animal mPET/ CT scanner (Inveon and Focus-220; Siemens Preclinical Solutions) 1 hour following the injection of radiotracer. Images were analyzed using Inveon Research Workplace 3.0. mPET and CT images are coregistered by visual alignment in all three planes (transverse, sagittal, and coronal). Regions of interest were manually drawn around the nonnecrotic areas of the tumor on the coregistered mPET/CT images. Activity in triceps muscle was used as nontarget tissue uptake. Activity measurements (Bq/cm 3 ) were divided by the decay-corrected injected dose (Bq) and multiplied by 100 to obtain a tissue uptake index expressed as % ID/g of tissue. Tumor to muscle (T:M) ratio was calculated as the ratio of % ID/g of tumor to that of muscle.
Immunohistochemistry
Four-micrometer sections of formalin-fixed paraffin-embedded mammary tumors were deparaffinized, rehydrated, heated in citrate buffer (pH 6), and stained using antibodies against PgR (Dako; A0089; 1:100). Positive signal was developed according to instructions from the EnVision HRP System (Dako) or MACH 4 (Biocare) followed by DAB chromogen.
Statistical analyses
All numerical results are presented as mean AE standard error of mean (SEM). The unpaired t test was used to determine the statistical significance between control and experimental groups whereas the paired t test was implemented to compare across different time points within the same group of animals. All tests are two-sided and a P value 0.05 was considered significant.
Results
Kinetics of [ 18 F]FES and [ 18 F]FFNP uptake in endocrinesensitive mammary tumors following ovarian ablation
A preclinical model of ERa þ breast cancer that faithfully recapitulates the pathophysiologic and developmental characteristics of human ERa þ breast cancer was used in this study (15, 22) . One of the advantages of this preclinical model is the availability of paired ERa þ PgR þ endocrine-sensitive SSM3 and endocrine-resistant SSM2 mammary tumor cell lines, as potential imaging biomarkers can be examined and compared in the two tumor systems (refs. 14, 15; Fig. 1A and 1B). Ovariectomy (OVX) was carried out as the treatment strategy to eliminate estradiol production by the ovaries (Fig. 1A and 1B) . Because the contribution of extragonadal aromatase activity in the mouse is negligible due to the lack of extragonadal-specific promoters in the mouse aromatase gene loci (23) , OVX mirrors ovarian suppression plus aromatase inhibition (AI) for premenopausal women or AI alone for postmenopausal women. Using this treatment protocol, we observed that the growth of the SSM3 mammary tumors was blunted by estrogen-deprivation therapy (Fig. 1A) . In contrast, progression of the SSM2 mammary tumors remained unaffected (Fig. 1B) .
We first sought to determine whether an acute reduction in [ 18 F]FES uptake could be observed in hormone-dependent SSM3 mammary tumors after estrogen-deprivation therapy. A tissue biodistribution study was carried out on sham-operated SSM3-bearing mice (Sham) and on tumor-bearing mice that were ovariectomized for 2, 3, or 4 days (D2, D3 or D4, respectively; Fig. 1C) . Tumor, uterus, muscle, and blood were harvested from these mice, and radioactivity was measured in the indicated organs. [
18 F]FES uptake in the SSM3 tumors did not change significantly after ovarian ablation (Fig. 1C) . Interestingly, [ 18 F]FES uptake in the uterus was transiently reduced on day 2 after OVX and returned to basal levels on days 3 and 4 after OVX, mimicking a short-term transient regulation of uterine ERa by E2 previously noted by others (24) .
In contrast with FES-PET, [ 18 F]FFNP uptake in the SSM3 tumors was reduced gradually over the course of 4 days following OVX (Fig. 1D) . By day 4 after OVX, tumor FFNP uptake was decreased by 40% compared with that in the tumors of sham-operated mice (P ¼ 0.01). 18 F]FFNP uptake in PgR-rich organs, such as tumors and uterus, was blocked only by the PgR-selective ligand R5020, not by the GR-selective ligand dexamethasone (Fig. 2) . In contrast, [ 18 F]FFNP uptake in the PgR-negative liver, which is due to metabolism and clearance, was not affected by either blocking agent (Fig. 2) . These findings therefore demonstrate that [ 18 F]FFNP binds specifically to PgR in the SSM3 mammary tumors.
Longitudinal FFNP-mPET/CT imaging of endocrine-sensitive mammary tumors
Having demonstrated the specificity and kinetics of [ 18 F]FFNP binding following OVX by biodistribution, we next evaluated the feasibility of noninvasive functional imaging using [ 18 F]FFNP in following the functional changes of ERa signaling in breast tumor cells over the course of endocrine therapy. SSM3 tumor-bearing mice were assigned to either sham-operation or OVX groups to standardize tumor size (Fig. 3) . Longitudinal FFNP-mPET/CT imaging was performed on the two cohorts of mice before surgery (day 0), and 3 and 4 days after surgery; these time intervals were chosen based on the kinetic study presented in Fig. 1D . Tumor to muscle (T:M) ratio of [ 18 F]FFNP uptake did not differ significantly between sham and OVX groups on day 0 before the surgery (Fig. 3A) . However, T:M ratios in the OVX mice were significantly lower than those in the sham mice on days 3 and 4 after the surgery (P ¼ 0.04 and P ¼ 0.0005, respectively; Fig. 3A and 3B) . Consistent with the biodistribution data presented in Fig. 1D , the T:M ratio in the OVX group was steadily decreased by 15% from the basal level on day 0 to day 3 after OVX (P ¼ 0.01), and by another 23% from day 3 to day 4 after OVX (P ¼ 0.009). The overall reduction in T:M ratio was 35% on day 4 after OVX, compared with the baseline measurement on day 0 (P ¼ 0.0002).
Results obtained from IHC also indicated that the number of PgR þ tumor cells in OVX SSM3 tumors was significantly diminished compared with the SSM3 tumors in sham-operated mice (Fig. 3C) . Importantly, tumor size in sham and OVX mice, as measured by caliper, did not differ on either days 3 or 4 postsurgery, indicating that the acute reduction in PgR expression in the OVX tumors occurs before a decrease in tumor size can be detected (Fig. 3D) . Taken together, these data clearly demonstrate that a reduction in PgR expression in endocrine-responsive mammary tumor cells following downregulation of ERa signaling can be measured serially and noninvasively using [ 18 F]FFNP.
Longitudinal FFNP-mPET/CT imaging of endocrine-resistant mammary tumors
Because the ERa þ PR þ mammary tumor cell line SSM2 is nonresponsive to ovarian hormone-depletion (Fig. 1B) , we hypothesized that PgR expression and thus [ 18 F]FFNP uptake would not be affected acutely by OVX. Indeed, FFNP T:M ratios of sham and OVX mice were not significantly different on days 0, 3, and 4 after surgery (Fig. 4A and 4B ). In addition, there was also no significant change in the T:M ratios in the OVX tumors as a group when the same tumors were monitored longitudinally from day 0 to days 3 or 4. Results from IHC analysis also indicated that PgR expression remained elevated in the OVX SSM2 tumors compared with sham SSM2 tumors, confirming the FFNP-PET imaging findings (Fig. 4C) . No significant difference in tumor sizes was observed between sham and OVX groups (Fig. 4D) . Together, acute reduction in tumor [ 18 F]FFNP uptake and PgR expression is associated with downregulation of ERa signaling in endocrine-sensitive tumor (SSM3), whereas the lack of reduction in FFNP uptake and PgR expression is associated with endocrineresistant tumor (SSM2).
Longitudinal FDG-mPET/CT imaging of endocrine-sensitive and -resistant mammary tumors [ 18 F]FDG is the most frequently used radiopharmaceutical to evaluate clinical response to therapies. We next examined whether FDG-PET would be suitable to monitor tumor response in the preclinical neoadjuvant setting of estrogendeprivation therapy. As shown in Fig. 5A , we did not observe any changes in [ 18 F]FDG uptake in the OVX-resistant SSM2 tumors following OVX. The T:M ratio of [ 18 F]FDG uptake remained unchanged on days 3 and 4 after OVX compared with the basal level before OVX. There was also no statistically significant difference in the FDG T:M ratio between sham and OVX tumors at all three time points.
In contrast with the SSM2 tumors, as SSM3 tumor growth was blunted by OVX, we expected to observe a decrease in [ 18 F]FDG uptake in the SSM3 tumors following OVX. To our surprise, the T:M ratio of [ 18 F]FDG uptake was indistinguishable between the sham and OVX groups at all the time-points examined (Fig. 5B) . There was also no difference in the T:M ratio between days 0, 3, and 4 in the OVX cohort. Within this time frame examined, the SSM3 tumors did not show significant tumor progression, as measured by caliper (Fig. 3D) . Therefore, levels of [ 
Longitudinal FFNP-mPET/CT imaging of endocrine-sensitive MCF7 mammary tumors
To extend and validate our findings, we tested whether the endocrine-sensitive ERa þ MCF7 human breast tumors displayed a similar FFNP binding profile following estrogen depletion. Because the MCF7 xenograft tumors grew at a slower pace than the SSM3 tumors, we monitored [
18 F]FFNP uptake after 6 days of estrogen withdrawal ( Fig. 6; ÀE2 group) . Consistent with the SSM3 results, [ 18 F]FFNP uptake in the MCF7 tumors was significantly reduced in the absence of estrogen on day 6 compared with the baseline levels on day 0 ( Fig. 6 ; P ¼ 0.0003). [ 18 F]FFNP uptake was also lower in the estrogen-depleted group (ÀE2) compared with the estrogen-supplemented group (þE2) on day 6 (P ¼ 0.0008). Taken together, rapid changes in [ 18 F]FFNP uptake following estrogen deprivation were also observed in the prototypical ERa þ MCF7 breast cancer xenograft model.
Discussion
In this study, we demonstrated that serial FFNP-PET imaging of ERa þ mammary tumors before estrogen-deprivation therapy and shortly after treatment was an effective approach to inform treatment response. A significant drop in [ 18 F]FFNP uptake levels in tumors posttreatment compared to pretreatment level predicted a positive response to estrogen-deprivation therapy. In % ID/g of tumor and muscle were calculated. Ratio of % ID/g in tumor to % ID/g in muscle [i.e., tumor to muscle ratio (T:M)] from Sham (n ¼ 6) and OVX mice before surgery (day 0; n ¼ 6) and on days 3 and 4 after surgery (n ¼ 6) were graphed. Ã , P < 0.05; ÃÃ , P < 0.01; ÃÃÃ , P < 0.001. ns, not significant. B, 3D maximum intensity projection (MIP) from coregistered mPET and CT images of representative mice bearing SSM3 mammary tumors. Serial images from the same mouse in each group are shown. Arrows, tumors. C, representative PgR IHC images of SSM3 tumors on day 4 following surgery. D, mean tumor diameter of SSM3 tumors before surgery (day 0) and after surgery (day 3). No significant difference in tumor size was observed between the two cohorts of mice. Representative results of two independent studies are shown. (25) . Because a decrease in tumor cell proliferation has been shown to be a good prognostic marker for endocrine therapies (26) (27) (28) , our preclinical study is a proof-of-principle to further support that monitoring the biologic and molecular consequences of ERa signaling is highly informative in predicting therapeutic response.
Our findings also indicated that FFNP-PET was more sensitive than FES-PET in monitoring the physiologic response of ERa signaling blockade. A reduction in [ Although it is possible that the levels of [
18 F]FES uptake in endocrine-sensitive mammary tumors might change at later time points following OVX, a delay in identifying endocrine-resistant patients could potentially lead to a delay in the initiation of alternative effective treatments. In addition, monitoring a decrease in ER levels by uptake of [
18 F]FES in response to estrogen deprivation is not a direct measure of ER function in the same way as is the measure of decreasing levels of PgR by [ 18 F]FFNP. FFNP-PET is also an early, more robust biomarker than changes in tumor size or FDG-PET in predicting endocrine response. Our previous study demonstrated that a change in [ 18 F]FDG uptake in the SSM3 tumors was detected 1 week after fulvestrant therapy (14) . Together with the current findings, these results suggest that a decrease in [ 18 F]FFNP tumor uptake precedes that in [ 18 F]FDG tumor uptake. Therefore, monitoring acute changes downstream of ERa signaling provides a more rapid assessment than measuring glucose metabolism in the tumors following estrogen-deprivation therapy.
In contrast with our current study, FDG-PET was demonstrated to be effective in predicting therapeutic response of the partial agonist tamoxifen or of low-dose estradiol therapy (9, 10, 29) . We have previously demonstrated that tamoxifen or low-dose estradiol causes metabolic flare in tumors such that an increase in tumor glucose metabolism and [ 18 F]FDG uptake 24 hours after estradiol administration is associated with a positive therapeutic response (9, 10, 29) . It will be interesting to test whether FFNP-PET can also be used as an imaging biomarker in these settings where metabolic flare is observed, and whether it provides a signal that is more rapid and robust than that of FDG-PET, as it is shown in this current study with estrogen deprivation.
Quantification of tumor cell proliferation by IHC analysis of Ki67 antigen has also been proven to be an effective biomarker in predicting outcome of endocrine therapies (26) . Inhibition of tumor cell proliferation by antiestrogens or estrogen deprivation is closely correlated with better prognosis (28, 30) . Because there is a strong concordance between Ki67 proliferation index and [ 18 F]FLT uptake in breast cancers (31) , future studies assessing the effectiveness of FLT-PET as an imaging biomarker for endocrine treatments will be needed.
In conclusion, we demonstrated that serial FFNP-PET imaging was more effective than FDG-PET and FES-PET in predicting response to estrogen-deprivation therapy in preclinical models of ERa þ breast cancer. In the context of our present study with estrogen-deprivation therapy and previous results with fulvestrant, one may extrapolate this biomarker approach to additional endocrine interventions, such as toremifene, which is also antagonistic in the breast. Measurement of acute changes in PgR expression by noninvasive FFNP-PET may be beneficial in a neoadjuvant setting so that a more aggressive treatment course can be implemented after surgery if the primary tumor is predicted to be endocrine-nonresponsive.
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